Provided by Tiger Trade Technology Pte. Ltd.

iShares Global Healthcare ETF

100.92
+0.06000.06%
Volume:42.57K
Turnover:4.29M
Market Cap:4.25B
PE:-98.14
High:101.08
Open:100.85
Low:100.51
Close:100.86
52wk High:107.69
52wk Low:90.24
Shares:42.15M
Float Shares:42.15M
Volume Ratio:0.88
T/O Rate:0.10%
Dividend:1.44
Dividend Rate:1.43%
EPS(TTM):-1.0283
EPS(LYR):-1.0283
ROE:-8.66%
ROA:0.90%
PB:1.10
PE(LYR):-98.14

Loading ...

Sector Update: Healthcare

MT Newswires Live
·
Sep 29

Market Chatter: Eli Lilly CEO Plans Larger Deals to Target New Disease Areas

MT Newswires Live
·
Sep 29

Lilly CEO Eyes Bigger Deals in Hunt for Pharma's 'white Spaces' - Bloomberg News

Reuters
·
Sep 29

Robert Hunter to be New UnitedHealthcare President

Reuters
·
Sep 29

Eli Lilly CEO tells Bloomberg sees more deals in untapped areas

TIPRANKS
·
Sep 29

Robert Hunter in Linkedin Post Says Stepping into New Role as President of Unitedhealthcare

THOMSON REUTERS
·
Sep 29

Lawyers in Alabama's TikTok Settlement Set to Earn $14 Million

Reuters
·
Sep 29

Teva Pharmaceutical's Duvakitug Could be Validated by Merck's Tulisokibart Results, Oppenheimer Says

MT Newswires Live
·
Sep 28

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

Johnson & Johnson (JNJ) Gets a Buy from Scotiabank

TIPRANKS
·
Sep 28

Taking Ozempic? a Routine Eye Exam Could Help You Understand Your Risk for Vision Loss

Dow Jones
·
Sep 28

FDA Approves AbbVie’s JUVMO for Adults with Parkinson’s Disease

Reuters
·
Sep 28

U.S. FDA Approves Abbvie's Juvmo™ (Tavapadon) for Parkinson's Disease

THOMSON REUTERS
·
Sep 28

Abbvie - Juvmo Expected to be Available in the U.S. in October 2026

THOMSON REUTERS
·
Sep 28

Eli Lilly price target raised to $1,500 from $1,400 at JPMorgan

TIPRANKS
·
Sep 28

Merck in License Pact Worth up to $2.13 Billion with SciBrunch Therapeutics

Dow Jones
·
Sep 28

Lilly Launches Initiative to Expand Diabetes, Obesity Drug Access

MT Newswires Live
·
Sep 28

Eli Lilly launches ‘Lilly Change the Course Commitment’

TIPRANKS
·
Sep 28

Merck enters global license agreement with SciBrunch Therapeutics for SPR2015

TIPRANKS
·
Sep 28

Merck Enters into Exclusive Global License Agreement with Scibrunch Therapeutics for Spr2015, an Investigational Oral Kras G12d (On) Inhibitor

Reuters
·
Sep 28